EUCTR2015-004775-78-RO
Active, not recruiting
Phase 1
A Randomized, Double-Blind, Placebo-Controlled, Parallel-GroupStudy to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Convergence Pharmaceuticals Ltd
- Enrollment
- 424
- Status
- Active, not recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Key Inclusion Criteria:
- •\- Men and women aged 18 to 75 years inclusive
- •\- Has body weight \=50 kg for men and \=45 kg for women
- •\- Must have diagnosis of neuropathic PLSR
- •\- Has duration of neuropathic (leg) pain of at least 6 months before Screening
- •Other protocol\-defined inclusion/exclusion criteria may apply.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 400
Exclusion Criteria
- •Key Exclusion Criteria:
- •\- Has pain of a different type in the legs (e.g. due to arthritis) that may interfere with the assessment of neuropathic pain in the legs.
- •\-Has planned surgical intervention for PLSR within the duration of the study.
- •\- Has a history of peripheral neuropathy (e.g., due to diabetes, alcohol consumption, other causes, or idiopathic) or evidence of peripheral neuropathy upon neurological examination
- •\- Has a history or risk of seizures or a history of epilepsy, clinically significant head injury, or related neurological disorders
- •\- Unable to discontinue prior to Day 1 any prohibited concomitant monoamine oxidase inhibitors (MAOIs), potent CYP3A4 inducers or inhibitors, potent UGT inducers or inhibitors, including over the counter preparations, herbal remedies, vitamin, mineral supplements, food or drinks as detailed in 11\.5\.1\.2
- •\- Is pregnant or lactating (female subjects only).
- •\- Male subject whose partner is pregnant
- •\-Has used paracetamol/acetaminophen at a daily dose of equal to or more than 2\.5g/day on 5 or more days during 7 consecutive days in the run in phase.\- Other protocol\-defined inclusion/exclusion criteria may apply.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging, Multicenter Study of the Efficacy of RWJ-333369 in the Prophylaxis of MigraineProphylaxis of migraine with or without aura, in patients with a diagnosis of at least 1-year duration.MedDRA version: 6.1Level: PTClassification code 10027607EUCTR2004-004162-33-ITJANSSEN-CILAG
Active, not recruiting
Phase 1
A study of Baricitinib in patients with LupusSystemic Lupus Erythematosus (SLE)MedDRA version: 21.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemicSystem Organ Class: 100000004859Therapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2017-005026-37-HREli Lilly and Company825
Active, not recruiting
Phase 1
Efficacy, Safety, and Pharmacokinetic Profile of ANB020 in Adults with Moderate to Severe Atopic DermatitisModerate-to-Severe Atopic DermatitisMedDRA version: 20.0Level: PTClassification code 10012438Term: Dermatitis atopicSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2018-000331-27-CZAnaptysBio, Inc.300
Completed
Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients with Type 1 or Type 2 Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDL-C Lowering Therapy.NL-OMON42569Sanofi-aventis20
Active, not recruiting
Phase 1
A Clinical Study in Parkinson’s Disease Patients With Moderate to Severe Abnormal Movements to See If JM-010 is Effective and Safe/Tolerable.Parkinson’s Disease Patients With Moderate to Severe DyskinesiaTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2017-003415-19-ESContera Pharma81